Today: 9 June 2026
Boston Scientific’s $14.5B Penumbra Deal Leads a Busy Day for BSX, VZ, GS, MS and ASTS
15 January 2026
2 mins read

Boston Scientific’s $14.5B Penumbra Deal Leads a Busy Day for BSX, VZ, GS, MS and ASTS

New York, January 15, 2026, 11:05 EST

  • Boston Scientific struck a deal to acquire Penumbra for roughly $14.5 billion, sending Penumbra’s shares up
  • Verizon handed out $20 credits following a 10-hour wireless outage that caught federal attention
  • Goldman Sachs and Morgan Stanley saw their quarterly profits rise, driven by increased dealmaking and trading activity

Boston Scientific (BSX) struck a deal to acquire Penumbra (PEN) for roughly $14.5 billion on Thursday, drawing attention to the medical device sector. This move came amid Verizon’s (VZ) ongoing outage issues and new earnings reports from Goldman Sachs (GS) and Morgan Stanley (MS).

The Penumbra deal marks the first significant healthcare takeover of 2026, arriving just as investors seek confirmation that large mergers are making a comeback. With borrowing costs down and regulators taking a softer stance, Wall Street has been buzzing—now this deal puts those hopes to the test.

Bank earnings reinforced the trend. Goldman and Morgan Stanley flagged stronger deal flow. At the same time, Verizon’s network disruption highlighted how fast operational slip-ups can spiral into regulatory scrutiny and customer credits.

Boston Scientific announced it will pay $374 per Penumbra share in a mix of cash and stock. CEO Mike Mahoney described Penumbra as “a well-established company” and said the deal taps into “new, fast-growing segments” within vascular care. Penumbra’s CEO Adam Elsesser highlighted the company’s focus on “deep innovation for complex diseases.” https://news.bostonscientific.com/2026-01-…

The deal prices Penumbra about 19% above its last closing price, sending its shares up over 12% early Thursday. Truist analyst Richard Newitter noted the acquisition plugs a hole in Boston Scientific’s neurovascular portfolio, bringing it back into brain clot-removal devices—a business it exited when it sold to Stryker more than ten years ago.

Verizon announced a $20 credit for hundreds of thousands of customers affected by a 10-hour outage on Wednesday, attributing the disruption to a software glitch. The company insisted the issue was not the result of a cyberattack and advised users still experiencing problems to restart their devices. The Federal Communications Commission said it will investigate the outage.

Goldman Sachs posted fourth-quarter profits that topped Wall Street expectations, driven by a boost in dealmaking and stronger trading. “The stock has been on a tear and already discounted these results,” said Gerard Cassidy of RBC Capital Markets, as Goldman shares slipped in premarket action. https://www.reuters.com/business/finance/g…

Morgan Stanley beat forecasts, thanks largely to a 47% surge in investment banking revenue, which hit $2.41 billion. CFO Sharon Yeshaya told Reuters she’s seeing “an accelerating pipeline in M&A and IPOs.” CEO Ted Pick highlighted geopolitical risks but emphasized the bank’s intent to remain “patient” on acquisitions. https://www.reuters.com/business/finance/m…

Together, the updates highlighted two types of catalysts investors often track. One involves deal activity — who’s acquiring whom, and what that signals about growth and confidence. The other covers the messier issues, such as outages and complaints, that can quickly draw regulatory attention.

AST SpaceMobile (ASTS) remained in focus, as investors kept an eye on the satellite-to-smartphone angle gaining traction in retail circles. A recent Motley Fool piece highlighted AST as a risky play, emphasizing that success in space-based cellular broadband hinges on execution, not just bold claims.

AST says its BlueBird satellites aim to deliver 4G and 5G service straight to standard smartphones. The company claims partnerships with over 50 mobile network operators, reaching nearly 3 billion subscribers. Founder and CEO Abel Avellan said they have a “fully-funded plan” to launch 45 to 60 satellites by 2026, with deployments scheduled through 2025 and 2026. https://ast-science.com/partners/ https://www.sec.gov/Archives/edgar/data/17…

Today’s major headlines come with caveats. Boston Scientific has to clear closing hurdles and brace for a deal that’s likely to dilute adjusted earnings per share in its first full year post-close. Verizon is under FCC scrutiny, with ongoing risks of customer churn. Banks’ deal flow hinges on markets remaining open and investor confidence staying intact. For AST and other space-telecom names, launch timetables, spectrum approvals, and funding requirements can shift abruptly — and the stocks often react accordingly.

Stock Market Today

  • NASDAQ Selloff Heightens Uncertainty in AI Sector Ahead of Key Week
    June 9, 2026, 3:28 PM EDT. The NASDAQ composite fell 2.9%, led by a sharp selloff in AI-related semiconductor stocks such as Micron Technology (-7.6%), Marvell Technology (-13.3%), and Advanced Micro Devices (-8.7%). The S&P 500 dropped 1.7% and the Dow Jones fell 0.8%. The volatility follows a week of steep moves, prompting concerns about whether the AI rally will sustain or face a prolonged downturn. Despite easing oil prices, which dropped 2.7% to $91.66 a barrel, tensions remain high over the Strait of Hormuz with geopolitical risks influencing markets. Treasury yields slightly retreated but remain elevated, signaling inflation pressures. Investors await upcoming U.S. inflation data and maintain cautious optimism amid a strong job market and pending major AI IPOs including OpenAI and SpaceX.

Latest articles

Marathon Digital Shares Fall as Bitcoin Move Renews Focus on AI Strategy

Marathon Digital Shares Fall as Bitcoin Move Renews Focus on AI Strategy

9 June 2026
MARA shares plunged 4.3% to $13.19 as bitcoin slipped below $62,000, highlighting that despite efforts to pivot toward AI and data-center infrastructure, the stock remains tightly tied to bitcoin’s price, with recent earnings showing revenue and bitcoin holdings down sharply and ongoing risks if crypto weakness persists.
UiPath Falls Again as AI Stocks Face Selling

UiPath Falls Again as AI Stocks Face Selling

9 June 2026
UiPath shares slid 5% to $10.63 as investors dumped AI-linked tech stocks despite the company posting its first-ever GAAP profit and raising full-year guidance, with market pressure and doubts about rapid AI-driven growth weighing on the stock.
XRP price today: Ripple token bounces as DTCC listing and Iran war headlines steer crypto traders

XRP Price Holds $1.10 as Key Level for Traders

9 June 2026
XRP slid 2.6% to $1.14 as crypto markets lost momentum, leaving the token just above key $1.10 support defended after last week’s four-month lows; traders are watching $1.13-$1.14 as support and $1.15-$1.20 as resistance, with broader risk-off sentiment and weak ETF inflows pressuring prices, while a break below $1.10 could signal further downside.
Ondas Stock Slides as Fresh Share-Resale Filing Tests Drone Rally

Ondas Stock Slides as Fresh Share-Resale Filing Tests Drone Rally

9 June 2026
Ondas Inc. shares fell 6.7% to $9.61 after filing a prospectus supplement for the resale of 2.7 million shares tied to its Omnisys acquisition, raising supply concerns as investors focus on defense orders and recent acquisitions; the block represents about 0.5% of shares outstanding and follows a volatile session with high trading volume.
Bitcoin Holds Focus at $60,000 as Market Watches Key Level

Bitcoin Holds Focus at $60,000 as Market Watches Key Level

9 June 2026
Bitcoin slid 2.8% to $61,683 as U.S. spot bitcoin ETFs saw $91.4 million in outflows and traders eyed Wednesday’s inflation report and next week’s Fed meeting; a break below the key $60,000 technical level could trigger further selling, with ETF redemptions and rate worries keeping buyers cautious.
POET Technologies stock climbs before the bell as call-option volume spikes
Previous Story

POET Technologies stock climbs before the bell as call-option volume spikes

Philip Morris stock edges up after PMI flags $20B+ U.S. investment push, FDA ZYN review ahead
Next Story

Philip Morris stock edges up after PMI flags $20B+ U.S. investment push, FDA ZYN review ahead

Go toTop